| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/12/2004 | US20040028677 Chimeric allograft tolerance induction, monitoring and maintenance |
| 02/12/2004 | US20040028667 Mixture containing probiotic bacteria; stability |
| 02/12/2004 | US20040028663 Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer |
| 02/12/2004 | US20040028652 Composition and method for stimulating immune response to pathogen using complex adenoviral vector |
| 02/12/2004 | US20040028650 Immunizing animals; inducing antibody response; complexing interleukin with carrier |
| 02/12/2004 | US20040028649 Regenerating cells |
| 02/12/2004 | US20040028647 Vaccines against cytokines and growth factors derived from malignant tumours |
| 02/12/2004 | DE10251709A1 Wirkstoffe zur Stimulierung der humanen beta-Defensine vom Typ 2 und/oder Typ 3 und kosmetische oder pharmazeutische Zusammensetzungen, die solche Wirkstoffe enthalten Agents for stimulating the human beta-defensins type 2 and / or Type 3 and cosmetic or pharmaceutical compositions containing such active |
| 02/12/2004 | DE10233676A1 New polypeptide allergens from fungi, useful in desensitizing vaccines and for diagnosis, also related nucleic acids, vectors and transformed cells |
| 02/12/2004 | CA2494311A1 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 02/12/2004 | CA2494240A1 Maxs as modifiers of the axin pathway and methods of use |
| 02/12/2004 | CA2493752A1 Papsss as modifiers of the axin pathway and methods of use |
| 02/12/2004 | CA2487528A1 Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
| 02/11/2004 | EP1388586A2 Identification of broadly reactive DR restricted epitopes |
| 02/11/2004 | EP1387889A2 Kinases and phosphatases |
| 02/11/2004 | EP1387888A2 Nucleic acid-associated proteins |
| 02/11/2004 | EP1387886A2 Proteases |
| 02/11/2004 | EP1387701A2 Immunoconjugates made of egg-yolk antibodies (igy), production and use thereof in diagnoses and therapy |
| 02/11/2004 | EP1387698A2 Method of preventing cell death using antibodies to neural thread proteins |
| 02/11/2004 | EP1387697A2 Methods of treating antibody-mediated pathologies using agents which inhibit cd21 |
| 02/11/2004 | EP1387696A2 Anti-ige antibody to treat ocular allergies |
| 02/11/2004 | EP1387695A2 Myostatin immunoconjugate and its use for immunisation |
| 02/11/2004 | EP1387694A2 Composition and method for treating cancer using herpes virus |
| 02/11/2004 | EP1387693A1 Saponin inactivated mycoplasma vaccine |
| 02/11/2004 | EP1387674A2 Hedgehog antagonists, methods and uses related thereto |
| 02/11/2004 | EP1387670A2 Immune modulation device for use in animals |
| 02/11/2004 | EP1387669A1 Concentrated w/o emulsion |
| 02/11/2004 | EP0892640B1 Enteric-coated pharmaceutical compositions of mycophenolate |
| 02/11/2004 | EP0862615B1 Immunity against pasteurella haemolytica leukotoxin |
| 02/11/2004 | EP0835124B1 Serum preparations for inhibiting retroviruses and tumor growth |
| 02/11/2004 | EP0804482B1 Cytokines that bind the cell surface receptor hek |
| 02/11/2004 | EP0655072B1 Immunological method for the detection of antibodies to equine herpesvirus type 1 and 4 glycoprotein G |
| 02/11/2004 | EP0506868B2 Immunologically active proteines from borrelia burgdorferi, related test kits and vaccine |
| 02/11/2004 | CN1474871A Inhibitor proteins |
| 02/11/2004 | CN1473854A Recombined IL4 antibody for treating IL4 insertion diseases |
| 02/11/2004 | CN1473853A Anti-bacteria endotoxin chicken ritellus antibody and its preparation and its use |
| 02/11/2004 | CN1473622A New use of combined monoclonal antibody in treating acute local hydrops caused by injury |
| 02/11/2004 | CN1137993C Recombinant adenovirus of bone morphogenetic protein and its method for exciting bone generation |
| 02/11/2004 | CN1137896C Vaccine for hoof-and-mouth disease and preparing method thereof |
| 02/11/2004 | CN1137727C Process for preparation of immune globulin for introvenous injection by dual inactivation of virus without protectives |
| 02/11/2004 | CN1137726C Method of prolonged suppression of humoral immunity |
| 02/11/2004 | CN1137725C Process for preparing hypotoxic vaccine for vincs of young parakeet |
| 02/11/2004 | CN1137724C Diagnosis reagent for blood cardiac muscle myosin light chain I of myocardiac infarction |
| 02/10/2004 | US6689938 Administering an antagonist of melanocortin stimulating hormone (msh) biological activity. |
| 02/10/2004 | US6689879 Nucleotide sequences coding nvelope protein for use in the prevention of viral diseases |
| 02/10/2004 | US6689876 Cloning and sequencing of allergens of dermatophagoides |
| 02/10/2004 | US6689869 Labeled humanized anti-CD18 antibodies and fragments and kits comprising same |
| 02/10/2004 | US6689866 Isolated polypeptide comprising specified amino acid sequence; membrane-bound or secreted polypeptide having semaphorin-like activity |
| 02/10/2004 | US6689787 Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia |
| 02/10/2004 | US6689757 Methods for vaccination and vaccines therefor |
| 02/10/2004 | US6689747 Use of insulin for the treatment of cartilagenous disorders |
| 02/10/2004 | US6689742 NY-ESO-1 peptide derivatives, and uses thereof |
| 02/10/2004 | US6689580 Growth factor |
| 02/10/2004 | US6689570 Antibody or antigen-binding sequences for use in the treatment of inflammatory bowel disease |
| 02/10/2004 | US6689562 Mammalian IAP gene family, primers, probes and detection methods |
| 02/10/2004 | US6689370 Vaccine adjuvant is a zinc, manganese or calcium salt of gluconic acid, fructoheptonic acid or glucoheptonic acid |
| 02/10/2004 | US6689369 Immunogenic pneumococcal protein and vaccine compositions thereof |
| 02/10/2004 | US6689368 Synthetic immunogens; hcv core, e1, e2 and ns3 t cell determinants |
| 02/10/2004 | US6689367 Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
| 02/10/2004 | US6689366 Conformational epitope; characterization of human papillomavirus infection; vaccines |
| 02/10/2004 | US6689364 Borrelia burgdorferi polypeptides and uses thereof |
| 02/10/2004 | US6689363 Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
| 02/10/2004 | US6689362 Method for treating T-lineage leukemias and lymphomas using a CD7-specific monoclonal antibody (TXU-7) linked to the pokeweed antiviral protein (PAP) |
| 02/10/2004 | US6689359 Ligands, including antibodies, showing reactivity against endocrine cells |
| 02/10/2004 | US6689355 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| 02/10/2004 | US6689354 Immunogenic preparation and method for improving the productivity of ruminant animals |
| 02/10/2004 | US6689338 Bioconjugates of nanoparticles as radiopharmaceuticals |
| 02/10/2004 | US6689118 Method of intradermally injecting substances |
| 02/10/2004 | CA2214247C Modulators of amyloid aggregation |
| 02/05/2004 | WO2004011673A1 Auto-stimulating cells and method for making and using the same |
| 02/05/2004 | WO2004011651A1 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 02/05/2004 | WO2004011650A2 Antigens encoded by alternative reading frame from pathogenic viruses |
| 02/05/2004 | WO2004011637A2 Modified adamts4 molecules and method of use thereof |
| 02/05/2004 | WO2004011611A2 Taci antibodies and uses thereof |
| 02/05/2004 | WO2004011490A1 A immounlogical epitope of the hiv strain type o and the uses thereof |
| 02/05/2004 | WO2004011486A2 Method for solubilizing hydrophobic peptides and use thereof for inducing an antitumoral and/or anti-infectious ctl response |
| 02/05/2004 | WO2004011484A2 Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion |
| 02/05/2004 | WO2004011476A1 Glyconjugates comprising carbohydrate epitopes, methods for theirsynthesis, and their use for the treatment or prophylaxis of cancer |
| 02/05/2004 | WO2004011028A1 Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
| 02/05/2004 | WO2004011027A1 Chimeric multivalent polysaccharide conjugate vaccines |
| 02/05/2004 | WO2004011026A1 Immunogenic compositions and diagnostic and therapeutic uses thereof |
| 02/05/2004 | WO2004010947A2 Humanized antibodies against human 4-1bb |
| 02/05/2004 | WO2004010935A2 Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies |
| 02/05/2004 | WO2004010934A2 Methods for the use of neurotoxin in the treatment of urologic disorders |
| 02/05/2004 | WO2004010900A1 Devices delivering therapeutic agents and methods regarding the same |
| 02/05/2004 | WO2003101482A3 Liposome vaccine formulations for fin-fish |
| 02/05/2004 | WO2003097089A3 Attenuation of metapneumovirus |
| 02/05/2004 | WO2003094829A3 Pathogen vaccines and methods for using the same |
| 02/05/2004 | WO2003094828A3 Cancer vaccines and methods of using the same |
| 02/05/2004 | WO2003093320A3 Antibodies specific for human cd22 and their therapeuatic and digagnostic uses |
| 02/05/2004 | WO2003089624A3 Fc receptor homolog, reagents, and uses thereof |
| 02/05/2004 | WO2003089001A8 Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus |
| 02/05/2004 | WO2003087818A3 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction |
| 02/05/2004 | WO2003084996A3 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine |
| 02/05/2004 | WO2003084560A3 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| 02/05/2004 | WO2003083442A3 Life sciences business systems and methods |
| 02/05/2004 | WO2003082255A3 Use of mob-5 in pain |
| 02/05/2004 | WO2003073994A3 Methods of treating nerve entrapment syndromes |
| 02/05/2004 | WO2003070282A3 Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue |
| 02/05/2004 | WO2003066091A3 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |